Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.47 |
| ▸ | MMP13 | P45452 | 2/20 | 0.47 |
| ▸ | MMP1 | P03956 | 2/20 | 0.45 |
| ▸ | MMP9 | P14780 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.43 |
| ▸ | STS | P08842 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15472723 | 1.00 | CYP2D6 (0.49) | CYP2D6GPR119MMP13MMP1MMP9 | |
| SCHEMBL17181765 | 1.00 | CYP2D6 (0.49) | CYP2D6GPR119MMP13MMP1MMP9 | |
| SCHEMBL222877 | 0.93 | CYP2D6 (0.54) | CYP2D6GPR119MMP13CYP1A2KMT2A | |
| SCHEMBL221063 | 0.93 | CYP2D6 (0.54) | CYP2D6GPR119MMP13CYP1A2KMT2A | |
| SCHEMBL221064 | 0.93 | CYP2D6 (0.54) | CYP2D6GPR119MMP13CYP1A2KMT2A | |
| SCHEMBL19001727 | 0.91 | CYP2D6 (0.55) | CYP2D6GPR119MMP13KMT2AMEN1 | |
| SCHEMBL5447212 | 0.91 | CYP2D6 (0.55) | CYP2D6GPR119MMP13KMT2AMEN1 | |
| SCHEMBL2298971 | 0.88 | CYP2D6 (0.49) | CYP2D6GPR119MMP13MMP1MMP9 | |
| SCHEMBL3127065 | 0.87 | ALDH1A1 (0.52) | GPR119MMP13MMP1MMP9KMT2A | |
| SCHEMBL184777 | 0.86 | CYP2D6 (0.60) | CYP2D6GPR119MMP13KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 162 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119977863-A | Synthesis process of (((2S) -4- (-) -3-hydroxy-4-oxo-1- ((S) -2- (-) -butan-2-yl) carbamic acid tert-butyl ester | 雅本化学股份有限公司 | 2025-05-13 | — | — | CN | claimed |
| CN-119977863-A | Synthesis process of (((2S) -4- (-) -3-hydroxy-4-oxo-1- ((S) -2- (-) -butan-2-yl) carbamic acid tert-butyl ester | 雅本化学股份有限公司 | 2025-05-13 | — | — | CN | disclosed |
| EP-3405192-B1 | BRUTON'S TYROSINE KINASE INHIBITORS | ZIBO BIOPOLAR CHANGSHENG PHARMACEUTICAL CO LTD (CN) | 2024-12-11 | — | — | EP | disclosed |
| EP-3630770-B1 | PYRAZOLO[3,4-B]PYRAZINE DERIVATIVES AS SHP2 PHOSPHATASE INHIBITORS | RELAY THERAPEUTICS INC (US) | 2024-08-28 | — | — | EP | disclosed |
| US-20240216380-A1 | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment | ACERTA PHARMA BV (NL) | 2024-07-04 | — | — | US | disclosed |
| US-20240197742-A1 | Therapeutic Combinations of a CD19 Inhibitor and a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2024-06-20 | — | — | US | disclosed |
| US-11976057-B2 | MrgX2 antagonists | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2024-05-07 | — | — | US | disclosed |
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-15 | — | — | US | disclosed |
| CN-116583509-A | Compounds and methods for treating cancer | 上海睿跃生物科技有限公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-116390917-A | MRGX2 antagonists | 葛兰素史密斯克莱知识产权发展有限公司 | 2023-07-04 | — | — | CN | disclosed |
| US-20090285772-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20090285772-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | SUPERGEN, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| EP-1719773-B1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1719773-A1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | Japan Tobacco, Inc. (JP) | 2006-11-08 | — | — | EP | disclosed |
| EP-0066993-B1 | QUINOLINE DERIVATIVES | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1985-01-30 | — | — | EP | disclosed |
| US-4435405-A | 2-(AMINOALKYLTHIO) SUBSTITUTED | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1984-03-06 | — | — | US | disclosed |
| EP-0066993-A1 | Quinoline derivatives | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1982-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049593-A1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | POLI, TERT, ZC3HAV1 | CYP2D6 1478/4885GPR119 3538/4885MMP13 1559/4885 |
| US-20240216380-A1 | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment | BTK, LYN, SYK | CYP2D6 4547/4885GPR119 2754/4885MMP13 1541/4885 |
| US-20240050428-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | GSPT1, GGT1, VHL | CYP2D6 3015/4885GPR119 2039/4885MMP13 565/4885 |
| US-20090285772-A1 | QUINOLINE DERIVATIVES FOR MODULATING DNA METHYLATION | DNMT1, DNMT3A, DNMT3L | CYP2D6 651/4885GPR119 4253/4885MMP13 4777/4885 |
| US-11976057-B2 | MrgX2 antagonists | MRGPRX2, MRGPRX1, MRGPRX4 | CYP2D6 2630/4885GPR119 43/4885MMP13 3147/4885 |
| US-20240197742-A1 | Therapeutic Combinations of a CD19 Inhibitor and a BTK Inhibitor | BTK, CD274, BCL9 | CYP2D6 3247/4885GPR119 1358/4885MMP13 4540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.